Change of Adviser

RNS Number : 2984Z

OptiBiotix Health PLC

10 December 2014

 



OptiBiotix Health plc

("OptiBiotix" or the "Company")

Appointment of Joint Broker

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, is pleased to announce the appointment of Hybridan LLP as joint broker with immediate effect.

OptiBiotix Health plc	www.optibiotix.com
Stephen O'Hara, Chief Executive	Contact via Walbrook below
Cairn Financial Advisers LLP Nominated Adviser	Tel: [phone]
Liam Murray / Avi Robinson
Peterhouse Corporate Finance Ltd Joint Broker	Tel: [phone]
Lucy Williams / Duncan Vasey
Hybridan LLP Joint Broker Claire Louise Noyce	Tel: [phone]
Walbrook PR Ltd Financial PR	Tel: [phone] or [e-mail]
Anna Dunphy	Mob: [phone]
Mike Wort	Mob: [phone]

About OptiBiotix- www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

END

 

 

APPLLFVRFALAIIS